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2-Amino-1,3,4-thiadiazoles as prospective agents 
in trypanosomiasis and other parasitoses
Parasitic diseases are a serious public health problem af fect ing 
hundreds of millions of people worldwide. African trypano-
somiasis, American trypanosomiasis, leishmaniasis, malaria 
and toxoplasmosis are the main parasitic infections caused by 
protozoan parasites with over one million deaths each year. 
Due to old medications and drug resistance worldwide, there is 
an urgent need for new antiparasitic drugs. 1,3,4-Thiadiazoles 
have been widely studied for me di cal applications. The chemi-
cal, physical and pharmaco kinetic properties recommend 
1,3,4-thiadiazole ring as a target in drug development. Many 
scientific papers report the antiparasitic potential of 2-amino- 
-1,3,4-thiadiazoles. This review presents synthetic 2-amino- 
-1,3,4-thiadiazoles exhibiting antitrypanosomal, antimalarial 
and antitoxo plasmal acti vi ties. Although there are insufficient 
results to state the quality of 2-amino-1,3,4-thiadiazoles as a 
new class of antiparasitic agents, many reported derivatives can 
be considered as lead compounds for drug synthesis and a pro-
mise for the future treatment of parasitosis and provide a valid 
strategy for the development of potent antiparasitic drugs.
Keywords: 2-amino-1,3,4-thiadiazoles, antiparasitic activity, anti-
 trypanosomal activity, antimalarial activity, antitoxo plas mal 
activity, inhibitory concentration
INTRODUCTION
Human parasitic diseases are caused by organisms of different sizes and shapes, from 
unicellular organisms (protozoa) to large-sized worms. Amoebiasis, giardiasis, leishmani-
asis, malaria, toxoplasmosis, trichomoniasis, trypanosomiasis, scabies, pediculosis and 
helminth infections are some of the many types of human parasitic infections that can lead 
to host‘s illness or death. Contaminated food or water, insect bites, and domestic animals 
are involved in the transmission of parasites (1, 2). Parasitic diseases are a serious public 
health problem affecting hundreds of millions of people worldwide. Most of these dis-
eases are common in low and middle-income countries of tropical and subtropical areas, 
among the indigent with limited treatment means. In such situations, the cost of health 
care is the dominant factor in treating the patient. The combination of climate and poverty 
contributes to the transmission of parasitic infections in these regions (2).
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Some of these illnesses have become known as “neglected tropical diseases” (NTDs). 
NTDs represent a group of chronic diseases caused by bacteria, viruses, protozoa and 
helminths. Most of them are parasitic infections that can last for years or even decades and 
have a high prevalence in developing countries of Africa, Asia and Latin America (3, 4). 
NTDs can cause severe pain and long-term consequences (e.g., blindness, disfigurement, 
deformity, cancer, neurological problems) (5). Multiple infections in a single individual are 
common (3). In 2005, the World Health Organization’s (WHO) NTDs department was es-
tablished. One year later, the United States Agency for International Development launched 
its NTDs program (6). Tropical diseases are currently issues of global concern. Malaria, 
leishmaniasis and trypanosomiasis are the protozoan parasitic diseases that are targeted 
for prevention, control, elimination and eradication by the WHO’s Division of Control of 
Tropical Diseases (7).
Nitrogen-containing heterocycles are found in a wide range of natural products and 
biologically active synthetic compounds (8–15). In addition, nitrogen-containing hetero-
cycles constitute a common structural unit of many marketed drugs (16, 17). There are five 
small molecules containing nitrogen-heterocycles (i.e., lisinopril, atorvastatin, amlodipine, 
omeprazole and losartan) ranked in the top ten of the 200 most prescribed drugs in the US 
in 2019 (Fig. 1) (18, 19). Moreover, nitrogen-containing heterocycles are found in many 
drugs used for the treatment of parasitic diseases. The nitroimidazole derivatives, metro-
nidazole and tinidazole, are widely known as antibacterial and antiprotozoal medications. 
These derivatives are very effective for giardiasis, trichomoniasis, amoebic liver abscesses, 
amoebic dysentery and anaerobic bacterial infections (20). Albendazole, mebendazole, 
 levamisole and pyrantel pamoate are the main drugs used for the treatment of soil-trans-
mitted helminthiases, the benzimidazole derivatives albendazole and mebendazole being 
the most commonly used drugs during the helminths infection prevention campaigns 
(Fig. 2) (21). Antimalarial drugs have been intensively studied over the last few decades. 
Although the artemisinin-based combination therapy (ACT) is currently the main strategy 













































Fig. 1. Nitrogen-heterocyclic drugs ranked in the US top ten of the most prescribed drugs in 2019 (18).
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 quinine (3), sulfadoxine (4) or pyrimethamine (5) still retain their value when ACT is not 
available (21, 22). In addition, pyrimethamine (5) in combination with sulfonamide deriva-
tives such as sulfamethoxazole (6) is a good treatment for toxoplasmosis (Fig. 3) (23).
Heterocycles containing both nitrogen and sulfur atoms are an important class of 
compounds in medicinal chemistry due to their interesting and wide biological applications 
(24). Five-membered nitrogen heterocycles, such as thiadiazole, are known as biologically 
active compounds. Among the four thiadiazole isomeric forms (e.g., 1,2,3-thiadiazole, 
1,2,4-thiadiazole, 1,2,5-thiadiazole and 1,3,4-thiadiazole), 1,3,4-thiadiazole ring is the most 
prevalent in medically significant synthetic compounds. A number of 1,3,4-thiadiazole- 
-containing drugs are currently on the market: acetazolamide and methazolamide as 
 carbonic anhydrase inhibitors, cefazolin, cefazedone and sulfamethizole as antimicrobial 
drugs, and megazol – a known antitrypanosomal agent (25–27).
The 1,3,4-thiadiazole moiety is also found in derivatives that have demonstrated bio-
logical activity and are currently under investigation. BMS-341 (7) is a glucocorticoid 













































































Fig. 2. Nitrogen-heterocyclic drugs used in the treatment of parasitosis.
Fig. 3. Nitrogen-heterocyclic drugs used in the treatment of parasitosis.
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activity in a chronic model of adjuvant-induced arthritis in rats, may have potential in 
treating human disease as a replacement for traditional glucocorticoid medicines (28, 29). 
1-[5-(6-Bromopyridin-2-ylamino)-1,3,4-thiadiazol-2-yl]-1-(4-methylthiazol-2-yl)ethanol (8) 
is a potent nanomolar inhibitor of the enoyl acyl carrier protein reductase (InhA) which 
showed excellent antimycobacterial activity in vitro and promising in vivo efficacy against 
Mycobacterium tuberculosis strains (Fig. 4) (29, 30).
In the last two decades, the number of scientific publications concerning the synthesis 
and biological investigation of 1,3,4-thiadiazoles has considerably increased (27). A look at 
the reference works shows that 1,3,4-thiadiazole has been investigated more than the  other 
isomers. Indeed, 1,3,4-thiadiazole derivatives have been widely studied for medical, 
agricultural and industrial applications (1, 16, 31, 32).
The rationale behind drug design is to incorporate heterocycles with favorable 
physicochemical properties into the structure of a biologically active molecule. Lipophilicity, 
polarity and water solubility are properties that can be improved and can influence the 
possible mechanisms of action of biologically active compounds (17). In addition, the bioiso-
steric replacement of a homocyclic ring with a heterocycle makes possible the synthesis of 
different analogs that interact more with the receptors (27). The 1,3,4-thiadiazole ring is a 
weak base due to the inductive effect of the sulfur atom and possesses relatively high 
aromaticity although lower compared to 1,2,5-thiadiazole due to the relative positions of the 
heteroatoms in the ring (32, 33). It is thermally stable and is relatively stable in acidic aqueous 
solutions but can undergo ring cleavage under basic conditions. The ring is also very 
electron-deficient due to the electron-withdrawing effect of the nitrogen atoms and relatively 
inert to electrophilic substitution but susceptible to nucleophilic attacks (32). The sulfur atom 
increases lipophilicity and offers great stability to the three-dimensional structure within 
the molecule (24). 1,3,4-Thiadiazoles carrying mercapto, hydroxyl and amino substituents 
can exist in tautomeric forms. On the other hand, 1,3,4-thiadiazole derivatives can make 
mesoionic systems (34). The mesoionic character of thiadiazoles gives good oral absorption 
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and good cell permeability, resulting in good bioavailability. Moreover, the mesoionic nature 
of 1,3,4-thiadiazoles enables these compounds to have strong interactions with biomolecules 
(e.g., DNA, proteins) (Fig. 5) (1, 27, 35).
2-Amino-1,3,4-thiadiazole and certain structurally related compounds have been 
known for 50 years as compounds with antitumor activity (24, 25, 36–44). Some com-
pounds in this class also exhibit uricogenic properties (24, 45). Both antitumor and urico-
genic activities can be prevented or reversed by nicotinamide (24, 46, 47). The cytostatic 
properties of 2-amino-1,3,4-thiadiazole and the antitrypanosomal activity of megazol are 
evidence of the biological potential of a 2-amino-1,3,4-thiadiazole moiety (27). In addition, 
many papers present 2-amino-1,3,4-thiadiazoles exhibiting antibacterial, antifungal, 
antimycobacterial (27) and antileishmanial activities (48). Moreover, due to the structural 
properties of 2-amino-1,3,4-thiadiazoles, they can participate in several chemical reactions 
and have significant use as intermediates for the synthesis of nitrogen-containing 
heterocyclic compounds (24). Due to our interest in the synthesis and biological activities 
of thiadiazoles (27, 48–54), the purpose of this review is to highlight some antiparasitic 
properties exhibited by derivatives having the 2-amino-1,3,4-thiadiazole moiety in their 
structure.
SOME PARASITOSES: STATE OF THE ART AND ANTIPARASITIC ACTIVITIES 
OF 2-AMINO-1,3,4-THIADIAZOLE SYSTEM
Antitrypanosomal activity
Trypanosoma parasites and trypanosomiases. – Eighteen NTDs have been identified by 
the WHO (55). It is estimated that over 1 billion people are infected with NTDs, with 
another 1 billion people at risk (5, 56). Among the NTDs, the parasitic infections caused by 
trypanosomatids have a huge impact on human health. Trypanosomatids (Euglenozoa 
phylum, Kinetoplastea class) are unicellular eukaryotic parasites responsible for serious 
diseases in humans and animals (57). Three major NTDs are caused by kinetoplastid 
infections: human African trypanosomiasis, American trypanosomiasis and various 
forms of leishmaniasis (58), resulting in more than 60,000 human deaths per year and the 
loss of approximately 5 million disability-adjusted life years (DALY’s) (48, 56, 57, 59–61).
The flagellated protozoans of the Trypanosoma genus are mainly transmitted to 
humans through the insects of the Triatominae subfamily (kissing-bugs, Hemiptera, 
Reduviidae family) and Glossina species (tsetse fly, Diptera, Glossinidae family) (62, 63). 
Human African trypanosomiasis (sleeping sickness, HAT) with the two forms – West 
African and East African trypanosomiasis, is caused by Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense, resp., and is transmitted by the bite of blood-feeding tsetse 
fly (59). The infective trypomastigote forms of the parasite penetrate into mammalian cells 
and convert into proliferative amastigotes, which are the mammalian replicative forms of 
the parasite. Rupture of these cells leads to the liberation of parasites and the proliferation 
of the infection (64, 65). Infectious trypomastigotes present in the salivary fluid of the flies 
produce a primary lesion in the skin known as a trypanosomal chancre that occurs 5–15 
days after the initial bite. The parasites multiply into the lymph and the blood of the person 
bitten and then disseminate throughout the body (66–68). During the early stage of the 
infection, patients experience unspecific symptoms such as headaches, fever and weakness, 
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pain in the joints, lymphadenopathy and stiffness. Infected people may or may not show 
signs of illness immediately but over time the parasites cross the blood-brain barrier (69). 
The late stage of HAT is defined by the entry of trypanosomes into the central nervous 
system causing neurological changes such as sleep disorder – including nocturnal 
insomnia and daytime somnolence giving rise to the name “sleeping sickness”, sensory, 
motor and psychiatric disorders. Patients inevitably progress to coma and death in the 
absence of proper medication (66, 69). T. brucei gambiense is responsible for more than 95 % 
of cases and causes chronic infections with the onset of symptoms after a prolonged 
incubation period of months or even years. T. brucei rhodesiense causes acute infections that 
can rapidly lead to central nervous system damage due to parasites crossing the blood- 
-brain barrier. African trypanosomiasis threatens the lives of approximately 60 million 
people in sub-Saharan Africa and is fatal if not treated (59, 66, 70).
American trypanosomiasis (Chagas disease) is caused by Trypanosoma cruzi and is a 
serious health concern in 21 countries of Latin America. Due to population mobility 
between Latin America and the rest of the world, Chagas disease has been increasingly 
detected in traditional non-endemic countries of America, such as the United States and 
Canada and some European and Western Pacific countries. WHO estimates that 6-8 
million people worldwide are infected with T. cruzi and 65 million people in the Americas 
live in areas of exposure and are at risk of contracting this disease (62, 71). Chagas disease 
is transmitted by the bite of blood-feeding kissing-bugs and consists of an initial acute 
phase that is followed by a chronic phase. The acute phase can remain asymptomatic for 
many years but eventually, it progresses into its chronic phase (59). Although mortality has 
significantly declined (about 12, 000 deaths per year), the disease can cause irreversible 
and chronic damage to heart leading to cardiac arrhythmias and cardiac dilatation (20–30 
%), digestive system damage leading to megaoesophagus and megacolon (5–10 %), and 
autonomic nervous system damage (70, 72).
Current pharmacotherapy for trypanosomiases. – Despite significant advances in under-
standing cell biology, etiology, the patho physio logy of parasitic infections and parasitic 
genome, there is currently no available vaccine for trypanosomiasis. It is due to the fact that 
parasitic infections do not stimulate immune system (73). In the absence of an available 
 vaccine for trypanosomiases, antiparasitic chemotherapy remains the only option for both 
clinical management and control of these diseases (59, 73). Effective drugs should be able to 
treat both stages of the disease or at least one of them. Pentamidine (9) and suramin (10) are 
used in early stages of African trypanosomiasis, whereas eflornithine (12) or the combination 
nifurtimox (13)-eflornithine (12) is approved for second-stage treatment. Melarsoprol (11), 
an arsenical drug with high toxicity, is also approved in later stages (Fig. 6) (58, 59). Chagas 
disease treatment currently depends on two nitroheterocyclic prodrugs: nifurtimox (13) and 
benznidazole (14). These two drugs are very effective against the circulating form of the 
parasite (trypomastigotes) if given soon after infection (acute phase), but not during the 
chronic stage of the disease (74).
However, current therapies of trypanosomiases have proven to be unsatisfactory 
because of limited efficacy, serious side-effects in long-term therapy, and difficulties in 
administration. There are also differences in sensitivity between the different strains of 
the parasite. cofactor, the time required to complete the treatment and the associated cost 
remain extremely limiting. Treatment failures are not uncommon and drug-resistant 
parasites have been identified. Given the deficiencies of the current treatment options, 
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there is a clear and urgent need for the development of improved drugs that are safe, 
inexpensive and orally available (58, 59, 74, 75).
Megazol and megazol derivatives. – Megazol (5-(1-methyl-5-nitroimidazol-2-yl)-1,3,4- 
-thiadiazol-2-amine) (15) is a nitroheterocyclic derivative containing the 2-amino-1,3,4- 
-thiadiazole moiety. Megazol showed antibacterial and antiparasitic activities, particularly 
against T. cruzi and T. brucei, as well as drug-resistant strains of Trypanosoma (74, 75). 
Megazol exhibited a trypanocidal effect in vitro against T. brucei brucei ten-times stronger 
than that of suramin with half of the maximally effective concentration (EC50) value of 0.01 
μg mL–1 (76). In vitro studies on bloodstream trypomastigote form of T. brucei showed 
similar activity of megazol (EC50 value of 4 × 10–5 mmol L–1) compared with that of suramin 
(EC50 value of 2 × 10–5 mmol L–1) (77). In vivo studies made on T. brucei brucei infected mice 
showed that a single intraperitoneal injection of 20 mg kg–1 of megazol cured the acute 
disease. However, megazol administered alone was not able to cure the mice carrying a 
subacute infection with central nervous system involvement (76, 77). The combination of 
megazol with suramin or melarsoprol in the treatment of T. brucei infections potentiates 
its trypanocidal effect and these results confirm the interest in testing drugs in combinations 
(74, 77).
Many pharmacological studies have focused on revealing the mechanisms that 
mediate the antiparasitic activity of megazol. Some of the suggested mechanisms include: 
the activation of megazol inside the parasite by nitroreductase enzymes – possibly via a 
second one-electron reduction (78), to a nitroso derivative which can bind to intracellular 
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macromolecules of epimastigotes (74); megazol can decrease the thiols and acts as thiol 
scavenger for trypanothione T(SH)2 in T. cruzi, the cofactor of the trypanothione reductase 
(TryR) – the detoxification enzyme which has been shown to be essential for the survival 
of the trypanosome parasites (74); megazol mediates DNA damage in T. brucei mutants 
lacking RAD51 – the main enzyme involved in eukaryotic DNA repair (79); megazol can 
block the nucleic acids and protein synthesis (74, 76). Although it is 3–4 times more effective 
against T. cruzi than nifurtimox (13) (74) and benznidazole (14), resp., megazol promoted 
chromosomal aberrations in mammalian cells. Due to its mutagenic and genotoxic 
properties, megazol is not used clinically, but it has been extensively used as a lead 
compound in the search for nitroaromatics with antitrypanosomal activity (61, 75).
Therefore, three megazol derivatives 16–18 obtained by substitution at the 4-position 
of the imidazole ring by electron-donating or electron-withdrawing groups (Fig. 7), were 
tested for the trypanocidal effect in vitro and in vivo. All derivatives were less active than 
the parent compound, megazol. The most active compound, 5-(4-bromo-1-methyl-5- 
 -nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-amine (17) was ten times less active (EC50 value 
0.15 μg mL–1) than megazol (EC50 value 0.01 μg mL–1). The methyl derivative (16) and 
trifluoromethyl derivative (18) were not trypanocidal even when the dose was elevated to 
10 μg mL–1 (76). An interesting feature of megazol, which is important for bioactivity, is its 
high bioavailability due to lipophilicity. Several studies have indicated that megazol enters 
the parasite by passive diffusion and the positive value of the partition coefficient (log P) 
has great influence (74, 75). Megazol also binds to the P2-aminopurine transporter, which 
also carries pentamidine, melarsoprol, adenine and adenosine. The carrier binds the 
substances through the –N=C–NH2 moiety, and the amine group must, therefore, be free 
(80). Since derivatives 16–18 appear to be more lipophilic than megazol, it should be easier 
for these derivatives to pass through the biological membranes and penetrate into parasites. 
They also possess a free amine group. However, no correlation between the lipophilicity 
and antiparasitic effect was observed. These results show the relationship between the 
hydrogen substitution at position 4 of the imidazole ring and the decrease or loss of 
trypanocidal activity (76, 77). Consistent with this observation was the result of biological 
tests performed on isomer 4-nitro-megazol. The location of the nitro group at position 4 
made the compound totally inactive (77).
Other analogues of megazol were also prepared, but the biological experiments 
indicated that megazol was the most active compound against T. brucei (100 % inhibition 
at concentration of 1.5 mmol L–1), T. cruzi (99 % inhibition at concentration of 3.1 mmol L–1) 
and Leishmania infantum (95 % inhibition at concentration of 6.2 mmol L–1), with no 
cytotoxicity to macrophages at active concentrations. However, it is worth considering two 
derivatives (Fig. 8). Although lower efficacy, activity was found against T. brucei (89 % 














R = CH3 (16), Br (17), CF3 (18)15
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inhibition at concentration of 3.1 mmol L–1) and T. cruzi (95 % inhibition at concentration of 
6.2 mmol L–1) for the 5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-amine (19) and against T. cruzi 
cultures (60 % inhibition at concentration of 12.5 mmol L–1) for the 5-(1-methyl-5-nitro-
4-(phenylthio)-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-amine (20) (77).
The efficacy of megazol in combination with suramin in T. brucei gambiense infected 
primates, including late-stage central nervous system infections, was also evaluated. 
Complete recovery was observed in five studied monkeys, without relapse of parasitemia 
during a 2-year follow-up (77).
2-Amino-1,3,4-thiadiazole derivatives as pteridine reductase-1 inhibitors. – As mentioned in 
a previous paper on antileishmanial properties of 2-amino-1,3,4-thiadiazole derivatives 
(48), one successful approach for the treatment of several microbial and parasitic infections 
is the use of drugs that attack essential enzymes in the biosynthetic pathway of folates (58). 
Folic acid and related pteridines, e.g., dihydrobiopterin (H2B) and tetrahydrobiopterin 
(H4B), are essential co-factors in all forms of life, playing critical roles in a variety of 
metabolic pathways such as DNA and RNA synthesis and amino acids metabolism (81). 
Two enzymes that are of particular interest in these pathways are thymidylate synthase 
(TS) and dihydrofolate reductase (DHFR). In trypanosomatids and other protozoans, 
DHFR is encoded as a fusion protein with TS (DHFR-TS), with the DHFR domain on the 
amino terminus and TS domain on the carboxy terminus (66, 81). The inhibition of DHFR 
does not cause the death of parasites by itself, but due to another key enzyme, pteridine 
reductase-1 (PTR1). PTR1 is a short-chain NADPH dependent dehydrogenase/reductase 
with an essential role in reducing conjugated (folate) and unconjugated (biopterin) pterins 
and is much less sensitive to inhibition by antifolates. PTR1 is responsible for the reduction 
of biopterin to its derivatives (e.g. H2B and H4B) and for the biosynthesis of 10 % 
tetrahydrofolate required for cellular metabolism and its activity is enhanced when the 
parasitic DHFR is drug-inhibited. PTR1 provides reduced pteridines and reduced folic acid 
required for the survival of the parasites and, therefore contributes to the failure of the 
treatment (58, 82). It seems that the role of PTR1 in Leishmania major and T. brucei is 
considerably different. Leishmania mutants lacking the PTR1 enzyme can be rescued in 
vitro by supplements with H2B or H4B and retain their infectivity in vivo. In contrast, 
knockdown of PTR1 levels in T. brucei abolishes the infectivity of the parasite in vivo and 
is lethal in vitro when the parasites cannot be rescued by H2B or H4B supplements. Thus, 
PTR1 is a promising drug target for the treatment of African trypanosomiasis (82, 83).
Some 2-amino-1,3,4-thiadiazole derivatives were identified as selective L. major PTR1 
(LmPTR1) inhibitors and antileishmanial agents in the combination with DHFR inhibitors 












Fig. 8. Megazol derivatives 19 and 20.
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studies have shown that the architecture of the co-factor binding site and the enzyme’s 
catalytic center are highly conserved. However, there are some differences in the placement 
of certain amino acids in the active site that significantly reduce the size of the substrate- 
-binding site of TbPTR1 and modify the chemical properties compared to LmPTR1 (85). 
Taking into account the morphology of Leishmania and Trypanosoma parasites, the 2-amino- 
-1,3,4-thiadiazole scaffold was further studied as a source of potential antitrypanosomal 
agents. A total of 57 compounds based on 2-amino-1,3,4-thiadiazole moiety, synthesized 
by Linciano et al. (58), were studied as potential TbPTR1 inhibitors. The in vitro antiparasitic 
activity against cultured T. brucei was also investigated. Some previously studied 
compounds, such as 3-(5-amino-1,3,4-thiadiazol-2-yl)pyridin-4-amine (21), 5-(1H-benzo[d]
[1,2,3]triazol-5-yl)-1,3,4-thiadiazol-2-amine (22) and 3-(5-amino-1,3,4-thiadiazol-2-yl)- 
-1-(thiophen-2-yl)propan-1-one (23), have shown competitive inhibition of LmPTR1 (48, 84), 
but have behaved as weak inhibitors of TbPTR1. However, derivative 22 showed promising 
T. brucei growth inhibition (67 % inhibition) and this observation guided the design of the 
newly 57 thiadiazoles in a structure-based approach (Table I) (58).
Previous docking studies have shown that the thiadiazole ring can be inserted between 
the nicotinamide ring of NADP+ and Phe113 of LmPTR1 (corresponding to Phe97 of TbPTR1) 
(58, 86). Indeed, the structure of the ternary complex of TbPTR1-NADP+-2-amino-1,3,4- 
-thiadiazole derivative (21, 22 and 23, resp.) showed that the thiadiazole ring is sandwiched 
between the nicotinamide ring of co-factor NADP+ and the phenyl ring of Phe97 of TbPTR1. 
A particular role plays the amino group at the 2-position of the thiadiazole derivative, 
which overlaps with the amino group at the 2-position of the pteridine ring, making hydrogen 
bonds with both TbPTR1 and NADP+. In addition, a series of polar interactions and hydrogen 
bondings stabilize the complex. Comparison between the binding modes of compounds 
21 or 23 and folate (TbPTR1-NADP+-2-amino-1,3,4-thiadiazole derivative complex and 
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TbPTR1-NADP+-folate complex, resp.) shows that the thiadiazole ring overlaps the 2-amino- 
-4-oxypyrimidine moiety in the folic acid structure. Thus, while maintaining the 2-amino- 
-1,3,4-thiadiazole scaffold that forms key bonds with the enzyme and the cofactor, various 
types of substituents designed to interact with the binding site residues were introduced at 
the position 5 (e.g., derivatives 24–26, 27–32 and 33–41) (58). Some derivatives, such as 25, 26, 
29, 33–41, exhibited an inhibition of TbPTR1 of over 30 % at a concentration of 0.05 mmol L–1 
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with half of the maximal inhibitory concentration (IC50) values in the range of 0.016–0.112 
mmol L–1 showing that the inhibition was improved by two to 12-fold compared to the first 
studied compounds 21, 22 and 23 (IC50 > 0.2 mmol L–1) (Tables II–IV). Taking into account 
that both TbPTR1 and TbDHFR use dihydrofolic acid as a substrate, the 1,3,4-thiadiazole 
derivatives were also tested as TbDHFR inhibitors. However, the compounds did not show 
any potential as TbDHFR inhibitors (58).
The 2,5-diamino-1,3,4-thiadiazole moiety proved to be a good scaffold, and derivatives 
33–41 were the most active inhibitors. N2-([1,1’-biphenyl]-4-ylmethyl)-1,3,4-thiadiazol-2, 5- 
-diamine (37) and N2-[2-(thiophen-2-yl)ethyl]-1,3,4-thiadiazol-2,5-diamine (38) showed the 
best IC50 values (0.016 and 0.025 mmol L–1, resp.). In these structures, the thiadiazole ring is 
usually linked to an aromatic ring in the side chain. These two aromatic domains are con-
nected by a flexible chain of 2–3 atoms, the nitrogen atom in position 5 being one of them. 
The second amino group at C-5 of thiadiazole ring also plays a role in the stability of the 
complex, allowing the formation of additional bonds with both the cofactor and the enzyme. 
Molecular docking studies have shown that larger compounds, which are also more active, 
are locked in the complex in a binding orientation very similar to that of folic acid. The authors 
concluded that there is a higher probability of enzyme inhibition for bulky derivatives, such 
as (37), capable of mimicking the orientation of folic acid into the complex (58).
The in vitro antiparasitic activity against cultured T. brucei was also investigated (Tables 
II–IV). Some derivatives such as 24, 25, 26, 27–32 and 36 caused over 75 % of parasite inhibi-
tion. However, these compounds exhibited low enzyme inhibition (< 50 % inhibition of Tb-
PTR1 at 0.05 mmol L–1) and possibly have a different target. On the other hand, there are the 
derivatives 37 and 38 that showed the highest TbPTR1 inhibition (73 and 79.8 %, resp.), but 
poor antiparasitic activity against T. brucei. It seems that there is no correlation between 
TbPTR1 inhibition and antiparasitic activity (58).
Previous studies have shown that simultaneous inhibition of two parasitic enzymes 
(DHFR and TS) ensures parasite survival due to increased activity of PTR1. Simultaneous 
inhibition of parasitic DHFR and PTR1 is probably an alternative that could lead to the 
 destruction of parasites (48, 87, 88). Therefore, the best TbPTR1 inhibitors 37 and 38 were 
evaluated in combination with a TbDHFR inhibitor (58). When the derivative 37 was 
combined with equimolar amounts of methotrexate (MTX), a TbDHFR and TbPTR1 inhibitor, 
the activity of MTX against T. brucei was improved (EC50 of MTX alone ~0.035 mmol L–1, EC50 
of MTX with 37 ~8.6 mmol L–1), suggesting that PTR1 inhibitors enhance antiparasitic 
activity of DHFR inhibitors, probably by decreasing the amount of reduced folates required 
for parasitic metabolism. A similar result was obtained for the combination of derivative 38 
with MTX, when the EC50 value of MTX was reduced two times (EC50 of MTX with 38 ~0.0175 
mmol L–1) (58).
The toxicity of derivatives at a concentration of 0.01 mmol L–1 was evaluated by some 
preliminary tests, such as cytotoxicity (e.g., WI-38, human lung fibroblasts), mitochondrial 
toxicity, cardiotoxicity (hERG inhibition), and inhibition of enzymes (e.g., cytochrome CYP450 
and Aurora B kinase) (58). Generally, thiadiazole derivatives showed a safe profile (< 30 % 
inhibition for mitochondrial toxicity, cardiotoxicity, CYP isoforms and Aurora B kinase and 
> 70 % for growth of WI-38 cells). Exceptions (e.g., cardiotoxicity, CYP2D6 inhibition, WI-38 
toxicity) were observed in the 2,5-diamino-1,3,4-thiadiazole derivative series (compounds 
33–41), suggesting that the second amino group at C-5 of thiadiazole ring can induce toxicity 
(Table V) (58).
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The cytotoxicity of compounds 37 and 38 at 0.1 mmol L–1, alone (~ 45 % of cell viability 
for compound 37, ~ 93 % of cell viability for compound 38, and ~ 48 % of cell viability for 
MTX, resp.) and in combination with equimolar MTX (~ 44 % of cell viability for the combi-
nation of 37 with MTX and ~ 60 % of cell viability for the combination of 38 with MTX, resp.), 
was evaluated using THP-1 macrophage-like cells (58).
These results showed that 2-amino-1,3,4-thiadiazoles have potential as future anti try-
panosomal agents and the combination of thiadiazole derivatives with DHFR inhibitors 
provides a good strategy for the future development of potent antiparasitic agents with 
synergistic effect (58).
2-Amino-1,3,4-thiadiazole derivatives as trypanothione reductase inhibitors. – A promising 
target for new antitrypanosomal drugs is the enzyme trypanothione reductase (TryR). 
Poisoning and selective inhibition of this enzyme can be the molecular mechanism of 
action for useful antitrypanosomatid agents, as it was shown that TryR is essential for the 
parasite survival by protecting them against oxidative stress (66, 89). Therefore, many 
researchers focus on the importance of the trypanothione pathway for the survival and 
infectivity of parasites (66, 90, 91). Trypano thione (N1,N8-bis(glutathionyl)spermidine) with 
the two forms, TS2 – oxidized form and T(SH)2 – reduced form of trypanothione, is a 
thiopeptide essential for parasites. Trypanothione synthesis is catalyzed by two key 
enzymes: trypanothione synthetase (TryS) and trypanothione reductase (TryR). TryS is 
responsible for the synthesis of trypanothione, while TryR maintains trypanothione in its 
reduced form T(SH)2 (Fig. 7) (48, 66, 92). Thiol-dependent redox metabolism is one of the 
unique metabolic traits that distinguish trypanosomatids from humans. A genetic feature 
of trypanosomatids is the lack of genes encoding glutathione reductase (GR) and 
thioredoxin reductase, the main enzymes in the redox systems of most living organisms 
(48, 92). In trypanosomatids, T(SH)2, T(SH)2-dependent antioxidant system (tryparedoxin 
TXN/tryparedoxin peroxidase system TXNPx) and TryR replace the antioxidant functions 
performed by glutathione (GSH), GSH-dependent antioxidant enzymes and glutathione 
reductase (GR) in most cells (90, 91, 93). T(SH)2 provides the reduction potential to several 
redoxin proteins that control metabolic functions. In addition, T(SH)2 is involved in the 
neutralization of xeno- and endobiotics, the coordination of iron-sulfur complexes and the 
reduction of ascorbate (92). Therefore, T(SH)2 is used by TXN/TXNPx system to reduce 
hydrogen peroxide, alkyl-hydroperoxide and other reactive oxygen species (Fig. 9) (90, 91, 
93). Due to the specific features of the antioxidant physiology of these parasites, different 
genetic strategies to validate the enzymatic pathway of T(SH)2 as drug targets in T. brucei 
have been studied. At 80–100 % down-regulation, most of the target enzymes were found 
to be essential for parasite survival, infectivity, or management of oxidative stress (94).
Some mesoionic derivatives such as 42, 43, 44 and 45 have already been studied to 
determine their antiparasitic activity and very potent or potent antileishmanial activities 
have been shown for all derivatives against three Leishmania species (L. amazonensis, L. 
braziliensis and L. chagasi) as compared to pentamidine as a standard drug (48, 95, 96). Their 
effect on the TryR activity of three Leishmania species was also investigated and the nitro-
derivative (45) provided very promising results (89). Since the protozoans of the genus 
Leishmania and Trypanosoma belong to the same family (Trypanosomatidae), this study was 
extended to the parasite that causes Chagas‘ disease, T. cruzi. The effects of mesoionic 
derivatives 42, 43, 44 and 45 (Fig. 10) against TryR from parasites extracts and against 
recombinant enzyme from T. cruzi were evaluated. TryR is an FAD-dependent 
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Fig. 9. Redox systems in mammals and trypanosomatids. GSSG – glutathione disulfide, H2O2 – hydro gen 
peroxide, ROOH – alkyl-hydroperoxide, ONOO – peroxynitrite, ROH – alcohol, NO2
– – nitrite, E – electro-


































































































oxidoreductase that uses NADPH as an electron donor and contains binding sites for FAD 
and NADPH, besides the substrate-binding site (89). Only 4-phenyl-5-(4-nitrostyryl)-1,3,4- 
-thiadiazolium-2-phenylamine chloride (45) inhibited TryR in the parasite extract. More-
over, derivative 45 inhibited 83 % of NADPH consumption by TryR in T. cruzi at 1 mmol 
L–1 compared with the control. On the other hand, preincubation of 1 mmol L–1 of nitro-
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derivative 45 with the recombinant enzyme from T. cruzi – TcTryR showed a 69 % inhibition 
of TcTryR, indicating that TryR could be a molecular target for derivative 45. The addition 
of 1 mmol L–1 of derivative 42 did not alter NADPH consumption in comparison with the 
control (89). Although the TryR assay identified derivative 45 as the only active enzyme 
inhibitor, all these mesoionic compounds have demonstrated antiparasitic activities. It is 
possible that several metabolic pathways in parasites are involved and other mechanisms 
of action independent of TryR inhibition could be identified by future studies (89).
However, the inconvenience is that TryR has a structural similarity to human GR, and 
the designing of selective TryR inhibitors can be difficult (66). Therefore, TryS remains the 
most promising target enzyme since it is a low-abundance and essential enzyme in 
 Trypanosomatidae parasites with no human homologs (93). Genetic and pharmacological 
tests on T. brucei brucei and L. infantum parasites have demonstrated the importance of TryS 
activity for the viability of the parasites (92). A kinetic model of T(SH)2 metabolism in 
T. cruzi predicted that, in order to diminish the T(SH)2 synthesis by 50 %, TryS inhibition 
by 63 % or TryR inhibition by over 98 % is required. Highly potent and specific TryR 
inhibitors are needed to affect the antioxidant capacities of the parasite, while moderate 
inhibition of TryS may be a promising target in drug development (94). In addition, TryS 
has several advantages as a molecular target candidate: it is encoded by a single copy gene, 
TryS has been shown to provide metabolic control to the trypanothione pathway in T. cruzi 
and kinetic information is available for multiple TryS (48, 92, 94, 97–99).
Mesoionic 1,3,4-thiadiazolium-2-phenylamine salts of natural piperine. – Piperine is a natural 
amide and the main secondary metabolite in Piper nigrum. Promising results concerning the 
in vitro activity of piperine against promastigote forms of L. donovani and in vivo studies on 
L. donovani-infected hamsters were the starting point for the synthesis of hybrid mesoionic 
salts containing the piperine moiety and the 1,3,4-thiadiazolium-2-phenylamine skeleton 
(100). The toxic effects of mesoionic derivatives were evaluated against different evolutive 
forms of T. cruzi (epimastigotes, trypomastigotes and amastigotes) and the toxicity of the 
most active compounds was evaluated against the host cells (murine macrophages). Among 
the derivatives that exhibited the lowest IC50 values on epimastigotes (e.g., 46, 47, 48 and 49, 
Fig. 11), 4-phenyl-5-[4-(3,4-methylenedioxyphenyl)-1(E)-3(E)-butadienyl]-1,3,4-thiadiazoli-
um-2-phenylamine chloride (46) possesses the best activity profile (IC50 value of 10.83 mmol 
L–1 against epimastigotes, 6.70 mmol L–1 against trypomastigotes and 1.35 mmol L–1 against 
amastigotes, resp.), showing an activity comparable to that of the reference drug, 
benznidazole (IC50 value of 2.21 mmol L–1 against epimastigotes, 6.61 mmol L–1 against 
trypomastigotes and 2.51 mmol L–1 against amastigotes, resp.) (Table VI) (100). Thus, 






 X = H, Y = H (42)        X = OMe, Y = H (43)
 X = H, Y = OMe (44)   X = NO2,  Y = H (45)
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derivative 46 can be considered a prototype in the development of new trypanocidal agents 
with good antiparasitic activity and low cytotoxicity. The higher antitrypanosomal activity 
exhibited by derivatives 46, 47 and 48 suggests that the conjugation between the mesoionic 
and methylenedioxyphenyl rings is an important structural feature for the activity of these 
compounds (100). Although derivatives 47, 48 and 49 exhibited significant toxic effects 
against T. cruzi epimastigotes, subsequent investigations were limited due to their toxicity 
to host murine macrophages. However, these results highlight the potential of natural 
piperine as a precursor of new molecules with antitrypanosomal activity that could be 
useful in the treatment of Chagas disease (100).
Antimalarial activity
Malaria and plasmodium parasites. – Malaria is one of the most destructive human 
diseases caused by protozoan parasites. Found in tropical and subtropical regions of the 
world, the malaria parasites belonging to the Plasmodium genus (Plasmodiidae family) are 
transmitted to humans through the bites of infected Anopheles mosquitoes (101, 102). There 
are five Plasmodium species responsible for malaria in humans: P. falciparum, P. malariae, 
P. ovalae, P. vivax and P. knowlesi. P. falciparum and P. vivax are the most infective species to 
humans (59, 101, 102). Plasmodium parasites have a complex life cycle and are dependent on 

















Table VI. Pharmacological and toxicological details of derivatives 46–49 (100)
Compd.
T. cruzi/IC50 (mmol L–1) Cytotoxicity
LD50 (mmol L–1)Epimastigotes    Trypomastigotes        Amastigotes
Piperine 7.31 ± 1.5 > max conc. allowed 4.91 ± 1.1 20.01 ± 3.35
46 10.83 ± 2.2 6.70 ± 1.7 1.35 ± 0.95 38.56 ± 4.6
47 4.13 ± 1.2 > max conc. allowed – 1.95 ± 0.5
48 0.64 ± 0.14 > max conc. allowed – 1.08 ± 0.23
49 13.42 ± 3.0 > max conc. allowed – 6.62 ± 2.3
Benznidazole 2.21 ± 0.85 6.61 ± 2.4 2.51 ± 0.7 –
> max conc. allowed – IC50 values are higher than the maximum concentration allowed.
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two hosts: Anopheles mosquitoes and humans (101). Malaria infection is established in 
humans following the injection of the sporozoite form of the parasite by female anopheline 
mosquitoes (103). In humans, parasites follow their asexual cycle of life when they grow and 
multiply in liver cells (hepatic stage), followed by the release of parasites into the blood-
stream and the invasion of red blood cells (blood-stage). Replication within these cells and 
their subsequent rupture leads to the clinical manifestations of malaria (101, 103). Mosqui-
toes take parasites as gametocytes during a blood meal and the parasite will begin the 
sexual cycle of life (101). The usual incubation period, from the time of infection with 
P.  falciparum to the initial symptoms, is 8–14 days in non-immune individuals. The incuba-
tion period can be much longer for patients with a certain degree of immunity. Symptoms 
of P. falciparum infection can range from mild fever (which makes it difficult to clinically 
distinguish from other similar illnesses) to a life-threatening disease with coma, respiratory 
distress, severe anemia or circulatory shock. Symptoms can change in 24 hours from a mild 
condition to life-threatening disease in young children and non-immune adults (103).
In 2017, P. falciparum was the cause of 99.7 % of malaria cases in the African region, 
while P. vivax was the predominant parasite in South America causing 74.1 % of cases of 
malaria (102). According to WHO, 219 million new cases of malaria and 435, 000 malaria- 
-related deaths in 90 countries were estimated in 2017. The African region has a 
disproportionately high rate in all cases of malaria worldwide. In 2017, the region was 
home to 92 % of malaria cases and 93 % of malaria deaths (102, 104). Children under the 
age of five in sub-Saharan Africa are particularly vulnerable, accounting for about two- 
-thirds of all global deaths caused by malaria (105). Substantial progress in malaria control 
has been achieved by African countries using basic tools to prevent diseases such as 
insecticide-treated mosquito nets and indoor residual spraying with insecticides as well 
as antimalarial drugs for treating patients. However, malaria and malaria-related deaths 
remain high, which raises the need for new tools to combat the disease (105, 106).
First malaria vaccine. – A first-generation vaccine, also known as RTS, S/AS01 (RTS, S), 
was developed by GlaxoSmithKline (GSK) over 30 years of research, including through a 
collaboration launched in 2001 with Malaria Vaccine Initiative (MVI) and a network of 
African research centers (106). RTS, S is the first and the only vaccine that demonstrates 
partial protection against malaria among young African children, the population most 
affected by the disease. RTS, S acts against P. falciparum, the most prevalent malaria parasite 
in Africa (105). Infection is prevented by inducing humoral and cellular immunity with 
high antibody titers that block the parasite from infecting the liver (107). The European 
Medicines Agency (EMA) announced in 2015 that the benefits of TRS, S in preventing 
malaria outweigh the potential risks (105, 108). WHO announced the launch of the first 
malaria vaccine by the Government of Malawi in a pilot program on 23 April 2019. It will 
be followed by Ghana and Kenya in the near future (109). However, RTS, S is only 
moderately effective and its introduction is unlikely to diminish the demand for 
antimalarial drugs (110). Therefore, the vaccine is a complementary malaria control tool 
that can be added to the recommended WHO measures for malaria prevention (e.g., the use 
of insecticide-treated bed nets, insecticide spray), malaria prompt diagnosis, and effective 
antimalarial treatment (103, 105, 106, 109).
Current pharmacotherapy for malaria. – Current malaria treatment still depends on 
chemotherapy. According to WHO, all uncomplicated malaria infections caused by 
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P. falciparum or P. vivax should be treated with artemisinin-based combination therapy 
(ACT). In areas where chloroquine-resistant P. vivax is not found, the infection can be 
treated with chloroquine (1). Primaquine (2) should be added to antimalarial treatment in 
order to reduce the transmission of the infection and to prevent relapses. Severe malaria 
should be treated with quinine (3) or with injectable artemisinin derivatives – artemether 
or artesunate, followed by ACT (102). The WHO currently recommends three malaria 
prevention strategies for high risk groups: intermittent preventive treatment in pregnancy 
(IPTp) with sulfadoxine (4)-pyrimethamine (5); intermittent preventive treatment in infants 
(IPTi) with sulfadoxine (4)-pyrimethamine (5); and seasonal malaria chemoprevention 
(SMC) with amodiaquine (50) (Fig. 12) plus sulfadoxine (4) – pyrimethamine (5) for children 
aged 3–59 months in areas of highly seasonal malaria transmission (59, 102, 104). The 
majority of these drugs are blood schizonticides with different mechanisms of action that 
target the erythrocytic asexual stages of malaria parasites and thereby terminate clinical 
attacks of malaria (111). Although significant progress has been made in understanding 
the life cycle of the parasite and the mode of transmission, there are still challenges in the 
treatment and eradication of malaria for which new therapeutic agents, as well as the 
control of parasite transmission, will be needed (112). Unfortunately, all drugs currently 
available for the treatment of malaria have been associated with decreased efficacy and the 
emergence of drug-resistant parasites. Therefore, new antimalarial drugs with new modes 
of action and efficacy against multi-drug resistant parasites should be designed (59).
2-Amino-1,3,4-thiadiazole derivatives as potential antimalarial agents. – A large chemical 
library containing more than 250,000 compounds was evaluated for the discovery of oral 
antiplasmodial drugs in a blood-stage P. falciparum growth inhibition assay (112). The 
selection process involved a three-step in vitro assay (spot test, dose-response and 
cytotoxicity) followed by in silico analysis of the confirmed hits and in cerebro evaluation of 
the selected chemical structures. In addition, chemical diversity and physicochemical 
properties were also evaluated through computational analysis. Finally, the new 
chemotypes with the desired properties were synthesized and tested in a P. falciparum 
growth inhibition assay. One hundred seventy-eight compounds with EC50 < 0.001 mmol 














Fig. 13. The structural formula of compound 51.
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L–1 and selectivity index SI >10 were selected. Among them, N1-[5-(6-methoxypyridin-3-yl)
imidazo[2,1-b][1,3,4]thiadiazol-2-yl)cyclohexane-1,4-diamine (51) (Fig. 13.) and six of its 
analogues exhibited promising antiplasmodial activity (112).
Derivative 51 has shown consistent antimalarial activity in both high throughput 
screening (HTS) method and after synthesis with EC50 values of 0.297 mmol L–1 and 0.284 
mmol L–1 against P. falciparum strain 3D7 and P. falciparum strain NF54, resp. In addition, 
this compound indicated good physicochemical properties and a high ligand efficiency 
index (LEI) value of 19 and therefore provided a good chemical starting point (112).
Antitoxoplasmosis activity
Toxoplasma parasites and toxoplasmosis. – Toxoplasma gondii is an apicomplexan protozoan 
in the Sarcocystidae family that causes the toxoplasmosis, one of the most prevalent parasitic 
infections in humans and domestic animals. T. gondii is an intracellular parasite with 
widespread distribution in both developed and developing countries and the seropositive 
rates ranging from less than 10 to over 90 % (113, 114). It is estimated that one-third of the 
world’s population is infected by this parasite, with more than 2 million people affected 
every year in the European region. In addition, T. gondii can infect more than 200 warm-
blooded animal species causing toxoplasmosis in them (115, 116). According to WHO, it is 
estimated that 95 % of people with an immunocompetent system will not develop clinical 
symptoms when they are infected with T. gondii, or they may experience mild influenza- 
-like symptoms such as fever, headache or myalgia that quickly pass (116). However, T. 
gondii can cause serious pathologies such as ocular disorders (e.g., eye infection, decreased 
visual acuity, retinochoroiditis) and severe neurological disorders (e.g., toxoplasmic 
encephalitis, mental retardation, necrotic lesions of central nervous system, epilepsy, and 
schizophrenia) in neonates and immune-suppressed individuals such as HIV-AIDS 
positive, cancer or organ transplant patients (113, 117, 118).
T. gondii has a complex life cycle consisting of a sexual phase and an asexual phase. 
The sexual phase generates fertilized gametes (oocysts) from sexual replication and occurs 
in the small intestine of definitive hosts, the members of Felidae family (domestic cats and 
their relatives). The oocysts are shed in the cats’ feces and thus contaminate the water, food 
and environment. The excreted oocysts can last in the environment for 18 months. When 
ingested by humans, the sporozoites residing within oocysts or the bradyzoites residing 
in animal tissue cysts are released and are rapidly converted into the tachyzoite stage 
(asexual phase). Tachyzoites are the stage of rapid multiplication of the parasite and they 
invade almost any kind of cell, multiplying at intervals of six hours. Tachyzoites can be 
detected in the host‘s leukocytes or in the bloodstream where they circulate freely. These 
tachyzoites localize in brain, liver and muscle tissue and develop into bradyzoite tissue 
cysts (115, 118, 119).
T. gondii is an important foodborne pathogen. Humans usually become infected by 
horizontal transmission through ingestion or handling of undercooked or raw meat 
containing T. gondii cysts, through ingestion of food or water contaminated by oocysts 
from feline feces or through direct contact with cats or infected soil (114, 116). The parasite 
can be transmitted vertically as well. Thus, when women acquire the disease during or just 
before pregnancy, the protozoan can be transmitted trans-placentally (from mother to 
280
G. Serban: 2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses, Acta Pharm. 70 (2020) 259–290.
 
fetus) and fetal death or congenital defects can result. In very rare cases, the disease can 
also be transmitted through blood or transplanted organs (116, 118).
Current pharmacotherapy for toxoplasmosis. – The ideal treatment for toxoplasmosis is the 
inhibition of different stages in the life cycle of the parasite. Compared to mammals that 
extensively use exogenous folate, Toxoplasma mainly relies on folate synthesis pathways to 
produce most of the folate needed for metabolism (113). Therefore, the folate synthesis 
pathway is the best-known therapeutic target against Toxoplasma. Two main enzymes are 
targeted by the pharmaceutical products, dihydropteroate synthetase and dihydrofolate 
reductase (DHFR). The dihydropteroate enzyme is not found in mammalian cells and 
provides a specific target for selective antitoxoplasmosis agents (113).
The current treatment for toxoplasmosis consists in the use of pyrimethamine (5) 
(DHFR inhibitor) and sulfonamides such as sulfamethoxazole (6) or sulfadiazine 
(dihydropteroate synthetase inhibitors), supplemented with folinic acid. The effectiveness 
of this treatment is limited by the large amounts of necessary drugs and serious side-
effects such as hypersensitivity, haematological toxicity, teratogenicity, allergic reactions, 
bone marrow suppression and liver toxicity that occur in long-term treatment (117, 120). 
The treatment is also ineffective in removing the bradyzoite form of parasites located in 
the central nervous system (113, 117, 120). In order to reduce the transmission of parasite 
from mother to fetus, pregnant women can be treated with spiramycin, a macrolide anti-
biotic with low toxicity but limited activity against the parasite (59, 113). Additional drugs 
available include clindamycin, co-trimoxazole, azithromycin or atovaquone, but each of 
these drugs has their own inconvenience (117). In addition, Toxoplasma’s resistance to 
antitoxoplasmosis drugs has been reported particularly in neonates and pregnant women 
whose treatment requires special medication (32).
2-Amino-1,3,4-thiadiazole derivatives as potential antitoxoplasmosis agents. – Considering 
that compounds containing an imidazole ring exhibit antiprotozoal activity, Liesen et al. 
(121) synthesized some 2-amino-1,3,4-thiadiazole derivatives having a methyl-imidazolyl 
group structurally similar to megazol. In vitro studies against intracellular T. gondii showed 
complete morphological disorganization of tachyzoites following 24 hours incubation with 
Table VII. In vitro anti-toxoplasma activity of derivatives 52–55 (121)
Compd.
Infected cells (%) Mean number of intracellular parasites
Untreated 
(control)
Treated (mmol L–1) Untreated  
(control)
Treated (mmol L–1)
0.1 1 10 0.1 1 10
52 72 ± 7 13 ± 4 10 ± 1 0.3 ± 0.2 780 ± 76 103 ± 32 6 ± 1.6 2 ± 1.9
53 56 ± 8 28 ± 9 14 ± 4 0 444 ± 75 194 ± 40 79 ± 16 0
54 70 ± 7 12 ± 2 8 ± 1 1 ± 0.3 595 ± 45 147 ± 46 42 ± 12 11 ± 2.5
55 56 ± 4 22 ± 7 6 ± 2 3 ± 0.5 507 ± 56 139 ± 52 34 ± 15 13 ± 1.2
Hydroxyurea 59 ± 9 53 ± 7 4 ± 0.3 1 ± 0.3 487 ± 69 452 ± 58 6 ± 1.1 3 ± 2.8
Sulfadiazine 79 ± 11 64 ± 11 48 ± 15 36 ± 18 716 ± 191 570 ± 101 259 ± 114 115 ± 68
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the thiadiazole derivatives 52–55 (Fig. 14). This resulted in a significant decrease in the 
percentage of infected cells as well as in the average number of tachyzoites per cell at 
concentrations of 0.1, 1 and 10 mmol L–1, compared to hydroxyurea and sulfadiazine as 
standard drugs (Table VII) (121).
Thiadiazole derivatives 52–55 were very active against T. gondii at a concentration of 
0.1 mmol L–1 and showed low cytotoxicity in uninfected cells (median lethal dose LD50 > 
10 mmol L–1) and hence provided an interesting chemical scaffold for the discovery of 
drugs useful in the treatment of toxoplasmosis. These derivatives showed LD50 values 
between 0.07 and 0.6 mmol L–1 for infected cells and 0.05 mmol L–1 for parasites, indicating 
a higher activity than standard drugs (Table VIII) (121).
5-(5-Methyl-1H-imidazol-4-yl)-N-phenyl-1,3,4-thiadiazol-2-amine (52) was the most 
selective compound against intracellular parasites (13 % infected cells at a concentration 
of 0.1 mmol L–1 compared to hydroxyurea – 53 % and sulfadiazine – 64 %, resp.). According 
to SAR results, the electron-withdrawing or electron-donating substituents on the phenyl 
moiety did not substantially influence the anti-Toxoplasma activity (121).
CONCLUSIONS
Parasitic diseases have a huge impact on human health, as well as on social and 
economic life, especially in developing and economically disadvantaged regions of the 
world (59). Many of these diseases are caused by protozoan parasites, unicellular eukaryotic 
organisms belonging to the Protista kingdom. The main parasitic infections in humans are 








R = H ( );52 OCH3 ( );53 Cl ( );54 F ( )55
Fig. 14. Structures of thiadiazole derivatives 52–55.
Table VIII. LD50 values of derivatives 52–55 (121)
Compd.
LD50 (mmol L–1)
Uninfected cells Infected cells Intracellular parasites
52 > 10 0.6 0.05
53 > 10 0.1 0.05
54 > 10 0.08 0.05
55 > 10 0.07 0.05
Hydroxyurea > 10 > 10 0.5
Sulfadiazine > 10 > 10 6
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parasites, such as Toxoplasma gondii, Trichomonas vaginalis, Giardia lamblia and Entamoeba 
histolytica cause frequent infections with widespread distribution in both developing and 
developed countries (122).
Many people in tropical areas suffer from poor nutrition, poor living conditions and, 
therefore, poor health. As a result, they suffer from diseases that affect humans around the 
world. In addition, they must endure the serious consequences of diseases specific to their 
geographical areas: the so-called tropical diseases. Diseases such as African sleeping 
sickness, Chagas disease, leishmaniasis, malaria or toxoplasmosis cause pain and suffering 
from deformities to internal organs disorders, heart and brain damage and death. Delayed 
treatment of these diseases can cause serious or even fatal consequences, especially in 
sensitive groups such as children and pregnant women, which should receive medication 
as soon as possible and without any side-effects. Some of these diseases are no longer 
limited to the tropics. Tourism, trade, business travel and immigration have brought cases 
of these diseases to the industrialized world, where health systems are not used to diagnose 
them. Therefore, tropical diseases are currently issues of global concern. Leishmaniasis, 
malaria and trypanosomiasis are protozoan parasitic diseases that are targeted for 
prevention, control, elimination and eradication by the WHO’s Division of Control of 
Tropical Diseases (3, 7).
Although significant advances have been made in the treatment of parasitic diseases 
over the last decade, currently available chemotherapy is far from satisfactory. The lack of 
an approved vaccine for any human parasitic disease, combined with the insufficient effi-
cacy and excessive toxicity of the drugs, as well as the increased resistance, has spurred 
research to find new alternatives (59, 101). Several research groups belonging to pharma-
ceutical companies or academia are involved in the synthesis of heterocyclic compounds 
with potential antiparasitic activity. In order to alleviate the increasing drug resistance, a 
good solution is the production of new compounds with different mechanisms of action 
and several groups of scientists have done research not only in the field of new antiparasitic 
drugs synthesis but also in molecular parasitology to discover molecular targets in 
parasitosis therapy. It has been shown that the thiadiazole ring is a structural component 
of biologically active natural, as well as synthetic compounds. Among the four isomers, 
1,3,4-thiadiazole derivatives are the most studied due to the wide spectrum of 
pharmacological activities, proving a significant utility in the development of biologically 
active compounds. Literature surveys report the antiparasitic properties of 2-amino-1,3,4- 
-thiadiazole derivatives. Taking into account the reactivity of the amino group in the 
derivatization process, 2-amino-1,3,4-thiadiazole moiety can be an excellent scaffold for 
future antiparasitic derivatives. The amino group attached to the 1,3,4-thiadiazole ring 
will probably be the focus of future research and will take full advantage of its special 
properties. The 1,3,4-thiadiazole ring is a very stable scaffold and the introduction of 
different kinds of substituents is a challenging approach to obtain antiparasitic agents 
with improved potency and less toxicity. In addition, the chemical, physical and 
pharmacokinetic properties recommend the 1,3,4-thiadiazole ring as a target in the 
development of new drugs. Inhibition of several enzymes essential for the survival of 
parasites appears to be the molecular mechanisms of action for promising antitrypanosomal, 
antimalarial, antitoxoplasmosis and antileishmanial drugs, and several 2-amino-1,3,4- 
-thiadiazole derivatives have shown these effects. Although there are insufficient results 
to state the quality of 2-amino-1,3,4-thiadiazoles as a new class of antiparasitic agents, 
these derivatives can be considered a great promise for the treatment of parasitic diseases 
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and provide a valid strategy for the development of potent antiparasitic drugs. Modifica-
tions to improve the potential of these compounds through structural diversification are 
under progress in many laboratories around the world.
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